Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Transenterix Shares Trade Up 25% on FDA Filing for First Machine Vision System in Robotic Surgery

Shares of Transenterix opened 50% higher after the company reported that it has submitted a 510(k) submission to the FDA for the first machine vision system for use in robotic surgery. This morning, medical device company TransEnterix Inc. (TRXC:NYSE.American) , whic...
Streetwise Reports | January 15, 2020 |

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...
Streetwise Reports | January 3, 2020 |

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types

This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report. In a Feb. 20 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that CytoDyn Inc. (CYDY:OTCQB) plans to...
Streetwise Reports | March 1, 2019 |

Buzz on the Bullboards: Buying Binge or Sell-Off Frenzy?

Adrift in a sea of global economic uncertainty and confusion, last week was full of tough questions for investors on the Stockhouse Bullboards. Some of the most popular companies on the website suffered setbacks, while other small caps gained attention as investors looked...
Stockhouse Editorial | February 16, 2022 |

Oil & Gas Royalty MLP Benefits from 'Record Production in Q3/19'

The quarterly highlights are provided in a Raymond James report. In a Nov. 7 research note, Raymond James analyst John Freeman wrote that Kimbell Royalty Partners, LP (KRP:NYSE) "reported record production in Q3/19, making way for about an 8% sequential distribution...
Streetwise Reports | November 26, 2019 |

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also anno...
Streetwise Reports | October 23, 2019 |

Avid Bioservices' Shares Rise on Q2/20 Earnings and Confirmed Outlook

Shares of Avid Bioservices traded higher today, reaching a new 52-week high, after the firm reported Q2/20 earnings and reaffirmed its revenue guidance for Full-Year 2020. After the U.S. financial markets closed yesterday, biologics contract development and manufactur...
Streetwise Reports | December 11, 2019 |

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |

Target Price Increased on Oil & Gas Company 'Poised for Continued Growth'

A Raymond James report provided reasons for the upward revision and detailed areas of potential growth for this Texas-based entity. In a March 8 research note, analyst John Freeman reported that Raymond James increased its target price to $24 per share from $22 and reit...
Streetwise Reports | March 15, 2019 |

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic

An explanation of the categorization and its implications are provided in a Paradigm Capital report. In a May 30 research note, Paradigm Capital analyst Rahul Sarugaser reported that Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) lead product candidate ZW25 wa...
Streetwise Reports | June 10, 2019 |
1 2 3 4 5 6 7 8 9 10 ...
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested